

RESTORING THE BODY'S ABILITY TO PRODUCE INSULIN

Targeted RNA therapeutics for a functional cure in insulin-requiring diabetes

FUNDRAISING STATUS

Stage: Seed
Investment goal: \$5M
Use of funds: IND-enabling toxicology, CMC / manufacturing, and corporate operations

\$5M unlocks a matching, non-dilutive funding commitment from Breakthrough T1D

BUSINESS MODEL

Advance WT817 through IND-enabling studies and a first-in-human Phase 1 safety/efficacy inflection, then partner, pursue acquisition, or IPO.

Value is created by advancing and de-risking WT817 through preclinical and clinical development, while leveraging proprietary targeted RNA delivery, scalable manufacturing, and expansion to additional payloads.

SEEKING FROM GHVF

- Mission-aligned seed investors
- Introductions to diabetes, metabolic, and RNA strategists
- Physician/KOL, payer, and clinical translation support
- Partnership or pilot discussions that accelerate human trials

FOUNDERS



Warren Marcus, PhD
Co-founder & CEO
Co-inventor of Ankiva; helped build Altor BioScience through its ~\$1B acquisition. 20+ years in drug discovery and development.



Paolo Serafini, PhD
Co-founder
University of Miami associate professor and inventor of Wink's licensed technology.

1. PROBLEM

Diabetes accounts for 1 out of every \$4 spent on U.S. health care and creates a ~\$640B annual economic burden. Insulin-requiring diabetes remains managed, not cured: insulin cannot reproduce normal beta-cell pulses every ~5 minutes, while curative strategies are limited by poor beta-cell selectivity, systemic exposure, or invasive cell-therapy complexity.

2. SOLUTION / PRODUCT

WT817 is a modified RNA aptamer therapeutic designed to selectively target pancreatic beta cells and deliver therapeutic RNA to restore beta-cell mass. The BCT Platform can deliver payloads specifically to the pancreatic beta cell, enabling a finite intervention rather than lifelong disease management.

3. TARGET MARKET & CUSTOMER

Patient population: all Type 1 Diabetes (T1D) and ~25% of T2D.
Market opportunity: >\$15B annual U.S. potential, modeled from ~8M U.S. insulin users at conservative ~4% penetration and \$50,000 per treatment course. Primary exit/customer: pharma or strategic partners seeking differentiated diabetes and metabolic assets.

4. TRACTION / VALIDATION TO DATE

Human beta-cell proof: 10/10 WT817-treated mice became normoglycemic after regeneration of transplanted human beta cells.

- Diabetic model was dependent on human beta cells for glucose control
- Targeted delivery and regeneration demonstrated in vivo
- Favorable tolerability in initial safety studies
- Exclusive IP in major markets through 2045
- Breakthrough T1D support since 2013 and matching non-dilutive commitment
- T1D KOL statement at meeting: "Wink technology one of most likely to cure T1D"

5. WHY WINK WINS

- Targeted RNA may reduce systemic exposure and off-target safety concerns
- Scalable approach avoids the cost and complexity of invasive cell therapies
- Only known technology allowing specific targeting to pancreatic beta cells of all humans

6. NEAR-TERM INFLECTION POINTS

Seed round funds the nonclinical and manufacturing studies required to advance WT817 toward human trials: IND-enabling toxicology, CMC / manufacturing, and preparation for clinical development.

7. CAPITAL NEED & STRATEGIC SUPPORT

Raising \$5M seed capital. Wink is seeking investor introductions, diabetes/metabolic pharma relationships, physician and healthcare executive guidance, payer perspective, and strategic partnerships that can accelerate WT817 toward first-in-human testing.